Use of danaparoid sodium (Orgaran[sup ®] ) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases

Fernandes, Philip; Mayer, Richard; MacDonald, James L.; Cleland, Andrew G.; Hay-McKay, Christine
October 2000
Perfusion;Oct2000, Vol. 15 Issue 6, p531
Academic Journal
Heparin-induced thrombocytopenia (HIT) has become more prevalent in today's cardiac setting and has resulted in the need for alternative anticoagulant therapies. Danaparoid sodium, one alternative to heparin, has been used in six cardiopulmonary bypass procedures in this hospital. This clinical experience has resulted in the progressive refinement of a protocol for the 'safe' clinical use of danaparoid sodium. Although there were six positive outcomes with the use of danaparoid sodium, alternatives must be explored in order to find the optimal anticoagulant for the treatment of HIT.


Related Articles

  • Use of Argatroban for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy Smith, Alan I.; Stroud, Robert; Damiani, Peter; Vaynblat, Mikhail // European Journal of Cardio-Thoracic Surgery;Nov2008, Vol. 34 Issue 5, p1113 

    Abstract: The use of Argatroban for treatment of heparin-induced thrombocytopenia (HIT) and for percutaneous coronary intervention in patients with HIT is well described and FDA approved. The use of Argatroban for cardiopulmonary bypass remains off label and the subject of a few case reports. We...

  • Alternatives to unfractioned heparin for anticoagulation in cardiopulmonary bypass. von Segesser, L.K.; Mueller, X.; Marty, B.; Horisberger, J.; Corno, A. // Perfusion;Sep2001, Vol. 16 Issue 5, p411 

    Despite the progress made in the development of cardiopulmonary bypass (CPB) equipment, systemic anticoagulation with unfractioned heparin and post-bypass neutralization with protamine are still used in most perfusion procedures. However, there are a number of situations where unfractioned...

  • Heparin.  // Reactions Weekly;1/16/2010, Issue 1284, p26 

    The article presents the case of a 59-year-old man who developed thrombocytopenia while undergoing heparin treatment for anticoagulation. Five days following his first intake of heparin, the patient's platelet count dropped dramatically. Heparin was discontinued and bivalirudin was used as an...

  • Delayed thrombin generation is not associated with fibrinopeptide formation during prolonged cardiopulmonary bypass with hirudin anticoagulation. Belway, D.; Rubens, F. D.; Henley, B.; Babaev, A.; Mesana, T. // Perfusion;Sep2006, Vol. 21 Issue 5, p259 

    Patients with heparin-induced thrombocytopenia urgently requiring surgery with cardiopulmonary bypass (CPB) present a unique management challenge that must be addressed by the use of alternative anticoagulants. Although clinical success with the direct thrombin inhibitor hirudin has been...

  • Optimal Anticoagulation in Cardiovascular Surgery. Pifarré, Roque // Clinical & Applied Thrombosis/Hemostasis;Summer1995, Vol. 1 Issue 3, p173 

    Despite current developments in anticoagulant drugs, unfractionated heparin has remained the drug of choice for anticoagulation during cardiopulmonary by-pass surgical procedures. The use of heparin has been associated with problems. Heparin-induced thrombocytopenia, intra- and postoperative...

  • Protamine Reversal of Heparin After Cardiopulmonary Bypass Increases Lung Resistance, Not Elastance. Gilbert, Timothy B.; Barnas, George M.; Miller, David W.; Sequeira, Alejandro J. // Journal of Cardiovascular Pharmacology & Therapeutics;Sep1999, Vol. 4 Issue 3, p137 

    The article presents a study on increasing lung resistance through protamine reversal of heparin after cardiopulmonary bypass (CPB). It is observed that the changes in lung resistance after CPB were greatest in those patients who received the most nearly balanced doses of heparin and protamine....

  • A Comparison of Heparin and New Anticoagulants for Cardiopulmonary Bypass Surgery. Belougne-Malfattie, Emmanuelle; Aguejouf, Omar; Labrousse, Louis; Doutremepuich, Christian // Clinical & Applied Thrombosis/Hemostasis;Apr1998, Vol. 4 Issue 2, p118 

    Heparin is still the major anticoagulant of choice during CPB. but it may cause thrombocytopenia and severe bleeding in patients. In light of these complications, the development of new anticoagulant drugs seemed to be necessary for these patients. Many experimental studies focused on r-hirudin,...

  • Acute Gastrointestinal Bleeding in Anticoagulated Patients: A Prospective Evaluation. Tabibian, Neshan // American Journal of Gastroenterology;Jan1989, Vol. 84 Issue 1, p10 

    Acute gastrointestinal hemorrhage is one of the most feared complications of anticoagulation therapy. We prospectively evaluated 18 episodes of acute gastrointestinal bleeding in 17 patients anticoagulated with coumadin or heparin. Endoscopic examination revealed significant lesions irrespective...

  • danaparoid sodium.  // Royal Society of Medicine: Medicines;2002, p184 

    This article provides information on danaproid sodium, a version of heparinoid that is used as an anticoagulant. It has some advantages over heparin when used for prevention of deep-vein thrombosis, particularly in orthopedic surgery. Administration of the drug may cause thrombocytopenia, liver...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics